Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Anticancer medical application of evofosfamide

A technology for efsolamide and cancer, applied in the field of efsolamide, which can solve the problem of inability to effectively target tumors for a long time

Inactive Publication Date: 2020-01-14
SHENZHEN ASCENTAWITS PHARM TECH CO LTD
View PDF44 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] The above researches have triggered the development of the compound as a targeted anti-cancer drug by international pharmaceutical giants. After Merck purchased TH-302-related research projects from Threshold Pharmaceuticals, it conducted phase III clinical trials of the anti-tumor drug TH-302. The trial was to investigate the drug's therapeutic effect on soft tissue sarcoma and pancreatic cancer. However, in 2015, Merck announced the failure of the trial. Threshold Pharmaceuticals stated that the failure of the TH-302 clinical trial showed that the drug could not effectively target tumors for a long time and became A stable anticancer drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anticancer medical application of evofosfamide
  • Anticancer medical application of evofosfamide
  • Anticancer medical application of evofosfamide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0277] Cell Proliferation Experiment

[0278] Exponentially growing cells were seeded with different concentrations of TH-302 24 hours after inoculation. After drug addition, the plates were incubated at 37°C for 2 hours in an anaerobic chamber (Bactron II), hypoxic chamber (Hypoxystation) or standard tissue culture incubator. After washing, cells were cultured in normoxic complete medium for 72 hours. Viable cells were quantified using AlamarBlue. 50% growth inhibition (IC50) was calculated using Prism software.

[0279] In vitro clonogenic assay

[0280] Cells were seeded 24 hours before starting treatment. Cells were then incubated with drugs for 2 hours at defined oxygen concentrations. At the end of treatment, the washed cells were plated and placed in an incubator for 10 days. For VC-8, UWB1.289 and FANCA strains, cells were plated in triplicate in 6-well plastic plates with 500 to 1,000 cells per well and processed. TH-302 was cultured under hypoxic conditions fo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides anticancer medical application of evofosfamide. The evofosfamide (TH-302) or an analogue of the evofosfamide has a specific inhibiting effect on specific genetically altered cells, and specifically, cells with damaged DNA repair or tissue at least has one or more gene mutation of BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C,RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2, XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP or ERCC5. Therefore, the medical application of the evofosfamide (TH-302) or the analogue of the evofosfamide for treating tumor and cancer diseases of people with cancer of the specific gene mutation is provided.

Description

technical field [0001] The present invention relates to efsolamide, especially the treatment of efsolamide to the cancer or tumor of patients with specific gene mutation. Background technique [0002] TH-302 (Evofosfamide, cas number 918633-87-1) is a 2-nitroimidazole-triggered hypoxia-activated prodrug (HAP) bromoifosfamide. Under hypoxic conditions, the inactive TH-302 prodrug can release highly toxic Br-IPM (shown in Structural Formula 1 below). TH-302 has broad-spectrum biological activity in vivo and in vitro, specific hypoxia selective activation activity, induction of H2AX phosphorylation and DNA cross-linking activity, resulting in cell cycle arrest, so this compound has been developed by many pharmaceutical companies and scientific research institutes Development of anticancer drugs. [0003] [0004] However, in the past, when researchers screened the anticancer activity of TH-302, they often used the principle of hypoxia activation in structural formula 1 to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/675A61K31/664A61K45/06A61P35/00A61P35/02
CPCA61K31/675A61K45/06A61P35/00A61K2300/00A61K31/66A61K31/664A61P35/02
Inventor 段建新李安蓉
Owner SHENZHEN ASCENTAWITS PHARM TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com